Ra Capital Management Lowers Stake in Derma Sciences Inc (DSCI)

Peter Kolchinsky‘s Ra Capital Management has recently sold a total of 300,000 shares of Derma Sciences Inc (NASDAQ:DSCI). Following the disposal, the fund still holds a significant amount of over 1.69 million shares of the company. According to the filing with the SEC, Ra Capital sold the securities in two transactions, the average price amounting to $11.83 per share.

Peter Kolchinsky

The shares have been sold entirely from the account owned by Blackwell Partners, LLC, the filing also stated. According to the amount of shares disclosed by Derma Sciences Inc (NASDAQ:DSCI) in its latest 10-Q report, the stake held by Ra Capital amasses around 9.8% of the common stock, following the disposal of shares.

Medical technology company Derma Sciences Inc (NASDAQ:DSCI) is engaged in the wound care marketplace. Today, on January 14, the company announced about licensing exclusive rights for two products from BioD LLC. The products will be launched later this year and will expand Derma Sciences’ portfolio of wound care products.

Meanwhile, the stock of Derma Sciences Inc (NASDAQ:DSCI) remained basically flat over the past year. The company significantly expanded its net loss for the first nine months of 2013, which amounted to $18.54 million, versus $8.39 million. For the full year, analysts expect the company to post an EPS of -$1.47, which is significantly lower with comparison to -$0.27 posted in 2012.

Last month, Kevin Kotler‘s Broadfin Capital has raised its stake in Derma Sciences Inc (NASDAQ:DSCI). The fund disclosed ownership of 871,600 shares, up from  771,600 held earlier. Overall, Broadfin’s stake amasses 5.04% of the company’s common stock. At the same time, in the latest round of 13F filings, Baker Bros. Advisors, led by Julian Baker and Felix Baker reported a larger stake, which amasses 2.56 million shares, being increased by almost 90% during the third quarter.

On the other hand, in November, Peter Kolchinsky’s fund reported upping its position in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Currently, the fund holds some 23.4 million shares, which has been raised, in several transactions from 14.46 million disclosed by the fund in its latest 13F.

Disclosure: none

Recommended Reading:

Litespeed Management LLC Initiates Stake in FTD Companies Inc (FTD)

What you can Learn from a Hedge Fund Blog

Farallon Capital Management Adds Sycamore Networks Inc. (SCMR) To Its Equity Portfolio

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!